Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lumateperone (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Intra-Cellular Therapies
  • Most Recent Events

    • 20 Feb 2020 According to an Intra-Cellular Therapies media release, the company is also presenting today additional analyses of this study at the International Society for CNS Clinical Trials and Methodologies (ISCTM) Annual Scientific Meeting that further demonstrate the strength of this study.
    • 20 Feb 2020 Results of this study including post-hoc sensitivity analysis presented in an Intra-Cellular Therapies media release.
    • 08 Jan 2020 Results assessing efficacy and safety of Lumateperone for Treatment of Schizophrenia published in the JAMA Psychiatry
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top